134. Incidence, risk factors, and predictors of outcome of candidemia. Survey in 2

Italian university hospitals. / M. Bassetti, E. M. Trecarichi, E. Righi, et al. // Diagn

Microbiol Infect Dis. – 2007. – Vol. 58. – Suppl. 3. – P. 325–331.

135. Inflammatory response and clinical course of adult patients with nosocomial bloodstream infections caused by Candida spp. / H. Wisplinghoff, H. Seifert, R. P. Wenzel, et al. // Clin Microbiol Infect. – 2006. – Vol. 12. – Р. 170–177.

136. International Pediatric Fungal Network Results from a prospective, international, epidemiologic study of invasive candidiasis in children and neonates / W. J. Steinbach, E. Roilides, D. Berman, et al. // Pediatr Infect Dis J. – 2012. – Vol. 31. – Suppl. 12. – P. 1252–1257.

137. Invasive Candidiasis Statistics (webpage on the Internet) Atlanta: Centers for

Disease Control and Prevention. – 2012. (Accessed. October 24, –2013).

138. Invasive candidiasis treated in the intensive care unit: observations from a randomized clinical trial / M. J. DiNubile, R. J. Lupinacci, K. M. Strohmaier, et al. // Journal Critical Care. – 2007. – Vol. 22. – P. 237–244.

139. Kanafani, Z. A. Antimicrobial resistance: resistance to antifungal agents: mechanisms and clinical impact / Z. A. Kanafani, J. R. Perfect // World Journal of Clinical Infectious Diseases. – 2008. – Vol.46. – P. 120–128.

140. Kett, D. H. International Study of the Prevalence and Outcomes of Infection in Intensive Care Units (EPIC II) / D. H. Kett et al. // Critical Care Medicine. – 2011. – Vol. 39. – P. 665–670.

141. Kohli, R. Fungal arthritis and osteomyelitis / R. Kohli, S. Hadley // World Journal of Clinical Infectious Diseases. – 2005. – Vol. 19. – Р. 831–851.

142. Kreusch, A. Candidemia among adults in Soweto, South Africa, 1990–2007 / A.

Kreusch, A. S. Karstaedt // Int J Infect Dis. – 2013. – Vol. 17. – Suppl. 8. – P. 621–

623.

143. Lass–Flörl, c. The changing face of epidemiology of invasive fungal disease in

Europe. / C. Lass–Flörl // Mycoses. – 2009. – Vol. 52. – Suppl. 3. – P.197–205.

144. (23еще)Latin American (Invasive Mycosis Network Epidemiology of candidemia in Latin America: a laboratory-based survey. / M. Nucci, F. Queiroz–Telles, T. Alvarado–Matute, et al. // PLoS One. – 2013. – Vol. 8. – Suppl. 3. – P. 523–573.

145. Lewis, R.E. Overview of the changing epidemiology of candidemia / R.E. Lewis

// Curr Med Res Opin. – 2009. – Vol. 25. – Suppl. 7. – P. 1732–1740.

146. Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients: Part II Treatment / B. P. Guery, M. C. Arendrup, G. Auzinger, et al. // Intensive Care Med. – 2009. – Vol. 35. – P. 206–214.

147. Management and outcome of bloodstream infections due to Candida species in

England and Wales / C. C. Kibbler, S. Seaton, R. A. Barnes, et al. // J Hosp Infect. –

2003. – Vol. 54. – Suppl. 1. – P. 18–24.

148. Management of invasive pulmonary aspergillosis in non-neutropenic critically ill patients / R. J. Trof, A. Beishuizen, Y. J. Debets-Ossenkopp, et al. // Intensive Care Med. – 2007. – Vol. 33. – P. 1694–1703.

149. Marchetti, O. Invasive candidiasis in critically ill patients: does progressing knowledge improve clinical management and outcome? / O. Marchetti, P. Eggimann, T. Calandra // Curr. Opin. Crit. Care – 2010. – Vol.16. – P. 442–444.

150. Mensa, J. Treatment of critically ill patients with candidemia / J. Mensa, C. Pitart, F. Marco // Int J Antimicrob Agents. – 2008. – Vol.32. – Suppl. 2. – Р.93-97.

151. Messer, S. A. International surveillance of Candida spp. and Aspergillus spp.: report from the SENTRY Antimicrobial Surveillance Program (2003) / S. A. Messer, R. N. Jones, T. R. Fritsche // Journal of Clinical Microbiology. – 2006. – Vol. 44. – P. 1782–1787.

152. Morrell, M. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality / M. Morrell, V. J. Fraser, M. H. Kollef // Antimicrob. Agents Chemother.

– 2005. – Vol. 49. – P. 3640–3645.

153. Multidisciplinary approach to the treatment of invasive fungal infections in adult patients. Prophylaxis, empirical, preemptive or targeted therapy, which is the best in

the different hosts? / R. Zaragoza, J. Peman, M. Salavert, et al. // Ther. Clin. Risk

Manag. – 2008. – Vol.4. – P. 1261–1280.

154. Nagao, M. A multicentre analysis of epidemiology of the nosocomial bloodstream infections in Japanese university hospitals / M. Nagao // Clin Microbiol Infect. – 2013. – Vol. 19. – Suppl. 9. – P. 852–858.

155. National Healthcare Safety Network (NHSN) Team and Participating NHSN Facilities Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention 2009–2010. / D. M. Sievert, P. Ricks, J. R. Edwards, et al. // Infect Control Hosp Epidemiol. – 2013. – Vol. 34. – Suppl. 1. – P.1–14.

156. National surveillance of fungemia in Denmark (2004 to 2009) / M. C. Arendrup, B. Bruun, J. J. Christensen, et al. // Journal of Clinical Microbiology. – 2011. – Vol.

49. – Suppl. 1. – P. 325–334.

157. New enzyme immunoassays for sensitive detection of circulating Candida albicans mannan and antimannan antibodies: useful combined test for diagnosis of systemic candidiasis / B. Sendid, M. Tabouret, J. L. Poirot, et al. // Journal of Clinical Microbiology. – 1999. – Vol. 37. – P. 1510–1517.

158. No increase in primary nosocomial candidemia in 682 German intensive care units during 2006(to 2011 / E. Meyer, C. Geffers, P. Gastmeier, F. Schwab // Euro Surveill. – 2013. – Vol. 18. – Suppl. 24. – 158 p.

159. Norwegian Yeast Study Group Candidemia in Norway (1991 to 2003): results from a nationwide study / P. Sandven, L. Bevanger, A. Digranes, H. H. Haukland, T. Mannsåker, P. Gaustad // Journal of Clinical Microbiology. – 2006. – Vol. 44. – Suppl. 6. – P.1977–1981.

160. Nosocomial bloodstream infections in US hospitals: Analysis of 24, 179 cases from a prospective nationwide surveillance study / H. Wisplinghoff, T. Bischoff, S. M. Tallent, H. Seifert, R. P. Wenzel, M. B. Edmond // World Journal of Clinical Infectious Diseases. – 2004. – Vol. 39. – Suppl. 3. – P. 309–317.

161. Novel high-throughput screen against Candida albicans identifies antifungal potentiators and agents effective against biofilms / M. D. LaFleur, E. Lucumi, A. D. Napper, S. L. Diamond, K. Lewis // J Antimicrob Chemother. – 2011. – Vol. 66. – Suppl. 4. – P. 820–826.

162. Offit, P. A. The meningococcal vaccine–public policy and individual choices. / P.

A. Offit, G. Peter. // N. Engl. J. Med. – 2003. – Vol. 349. – Р. 2353–2356.

163. Pfaller, M. A. Epidemiology of invasive candidiasis: a persistent problem / M. A.

Pfaller, D. J. Diekema // Clin Microbiol Rev. – 2007. – Vol. 20. – Suppl. 1. – P.

133–163.

164. Pappas, P.G. Invasive candidiasis. / P.G. Pappas // Infect Dis Clin North Am. –

2006. – Vol. 120. – Suppl. 3. – P. 485–506.

165. Paradoxical effect of Echinocandins across Candida species in vitro: evidence for echinocandin-specific and Candida species-related differences / G. Chamilos, R. E. Lewis, N. Albert, et al. // Antimicrob. Agents Chemother. – 2007. – Vol. 51. – P.

2257–2259.

166. Paradoxical growth effects of the echinocandins caspofungin and micafungin, but not of anidulafungin, on clinical isolates of Candida albicans and C. dubliniensis / M. Fleischhacker, C. Radecke, B. Schulz, et al. // Eur. J. Clin. Microbiol. Infect. Dis. – 2008. – Vol. 27. – P. 127–131.

167. Peritonitis candidiásica Candida peritonitis / Alejandro Úbeda, Ana Loza

Vázquez, Cristóbal León Gil // Enfermedades Infecciosas y Microbiología Clínica.

– 2010. – Vol. 28. – Suppl. 2. – P. 42–48.

168. Playford, E. G. Antifungals in the ICU / E. G. Playford, P. Eggimann, T.

Calandra // Curr. Opin. Infect. Dis. – 2008. – Vol. 21. – P. 610–619.

169. Pharmacokinetic evaluation of fluconazole in critically ill patients / M.

Sinnollareddy, S. L. Peake, M. S. Roberts, et al. // Expert Opin. Drug. Metab. Toxicol. – 2011. – Vol.7. – P. 1431–1440.

170. Pound, M. W. Echinocandin pharmacodynamics: review and clinical implications

/ M. W. Pound, M. L. Townsend, R. H. Drew // J. Antimicrob. Chemother. – 2010.

– Vol.65. – P. 1108–1118.

171. Punithavathy, P. M. Antifungal susceptibility testing of Candida tropicalis biofilms against fluconazole using calorimetric indicator resazurin / P. M. Punithavathy, K. Nalina, T. Menon // Indian J Pathol Microbiol. – 2012. – Vol. 55.

– Suppl. 1. – Р. 72–74.

172. Rare Case of Septic Arthritis Caused by Candida krusei: Case Report and Literature Review / L. U. Huifang , Maria F. Marengo, Coralia N. Mihu, M. D. Guillermj Garcia–Manero // The Journal of Rheumatology. – Vol. 39. – Suppl. 6. – Р. 1308–1309.

173. Recurrent arthritis by Candida glabrata, a diagnostic and therapeutic challenge / M. Erami, H. Afzali, M. M. Heravi, A. Rezaei–Matehkolaei, M. J. Najafzadeh, M. Moazeni, S. Dolatabadi, L. Hosseinpour // Mycopathologia. – 2014. – Vol. 177. – Suppl. 5–6. – Р. 291–298.

174. Red Nacional De Laboratorios De Micologia Species distribution and susceptibility profile of yeasts isolated from blood cultures: results of a multicenter active laboratory–based surveillance study in Argentina / S. Córdoba, W. Vivot, M. E. Bosco–Borgeat, et al .// Rev Argent Microbiol. – 2011. – Vol. 43. – Suppl. 3. – P.

176–185.

175. Relative frequency of albicans and the various non-albicans Candida spp among candidemia isolates from inpatients in various parts of the world: a systematic review / M. E. Falagas, N. Roussos, K. Z. Vardakas // Int. J. Infect. Dis. – 2010. – Vol. 14. – P. 954–966.

176. Renal Candida tropicalis abscesses in a patient with acute lymphoblastic leukemia

/ W. Y. Li, V. C. Wu, W. C. Lin, Y. M. Chen // Kidney Int. – 2007. – Vol. 72. – Р.

382.

177. Retrospective analysis of epidemiology and prognostic factors for candidemia at a hospital in China, 2000–2009 / X. B. Zhang, S. J. Yu, J. X. Yu, Y. L. Gong, W. Feng, F. J. Sun // Jpn J Infect Dis. – 2012. – Vol. 65. – Suppl. 6. – P. 510–515.

178. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study

Group (EORTC/MSG) Consensus Group / B. De Pauw, T. J. Walsh, J. P. Donnelly, et al. // World Journal of Clinical Infectious Diseases. – 2008. – Vol. 46. - №12. – P. 1813–1821.

179. Richardson, M. Changing epidemiology of systemic fungal infections / M.

Richardson, C. Lass–Flörl // Clin Microbiol Infect. – 2008. – Vol. 14. – Suppl. 4. –

P. 5–24.

180. Risk factors and the incidence of candidemia in the intensive care unit: A 5-year cross-sectional study / N. Yapar, M. Akan, V. Avkan–Oguz, et al. // Proceedings of Twentieth European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). – 2010.

181. Risk factors for invasive fungal disease in critically ill adult patients: a systematic review / H. Muskett, J. Shahin, G. Eyres, et al. // Critical Care Medicine. – 2011. – Vol. 15. – P. 287–287.

182. Rodloff, A. C. Epidemiology and antifungal resistance in invasive candidiasis. / A. C. Rodloff, D. Koch, R. Schauman // Eur J Med Res. – 2011. – Vol. 16. – Suppl.

4. – P. 187–195.

183. Sanya. E. O. Candida meningitis in a suspected immunosuppressive patient—a case report. / E. O. Sanya, N. B. Ameen, B. A. Onile // West Afr J Med. – 2006. – Vol. 25. – Р. 79–81.

184. Secular trend in candidemia and the use of fluconazole in Finland, 2004–2007. /

E. Poikonen, O. Lyytikäinen, V. J. Anttila, et al. // BMC Infect Dis. – 2010. –312 p.

185. Spanish Candidemia Surveillance Group Nationwide sentinel surveillance of bloodstream Candida infections in 40 tertiary care hospital in Spain / R. Cisterna, G. Ezpeleta, O. Tellaria, et al. // Journal of Clinical Microbiology. – 2010. – Vol. 48. – Suppl. 11. – P. 4200–4206.

186. Species identification and antifungal susceptibility testing of Candida bloodstream isolates from population–based surveillance studies in two US cities from 2008 to 2011 / S. R. Lockhart, N. Iqbal, A. A. Cleveland, et al. // Journal of Clinical Microbiology. – 2012. – Vol. 50. – Suppl. 11. – P. 3435–3442.

187. Species and susceptibility distribution of 1062 clinical yeast isolates to azoles, echinocandins, flucytosine and amphotericin B from a multi-centre study / A. F. Schmalreck, B. Willinger, G. Haase, et al. // Mycoses. – 2012. – Vol. 55. – P. 124–

137.

188. Sudhakar, Devathi. Isolated pulmonary valve infective endocarditis in a middle aged man caused by Candida albicans: a case report / Devathi Sudhakar, Curry Bryan, Dosh Saumil // BMC Infect Dis. – 2014. – Vol. 14. - Suppl. 1. – 557 p.

189. Susceptibility of Candida biofilms to histatin 5 and fluconazole / K. Konopka, B.

Dorocka-Bobkowska, S. Gebremedhin, N. Duzgunes // Antonie Van

Leeuwenhoek. – 2010. – Vol. 97. – Suppl. 4. – P. 413–417.

190. Temporal assessment of Candida risk factors in the surgical intensive care unit / P. S. McKinnon, D. A. Goff, J. W. Kern, et al. // Arch. Surg. – 2001. – Vol. 136. – P. 1401–1408.

191. Temporal trends, risk factors and outcomes in albicans and non-albicans candidaemia: an international epidemiological study in four multidisciplinary intensive care units / A. Holley, J. Dulhunty, S. Blot, et al. // Int. J. Antimicrob. Agents. – 2009. – Vol. 33. – P. 554–557.

192. The central nervous system and infection by Candida species. / J. Sánchez-

Portocarrero, E. Pérez–Cecilia, O. Corral, et al. // Diagn Microbiol Infect Dis. –

2000. – Vol. 37. – Р. 169–179.

193. The changing epidemiology of healthcare-associated candidemia over three decades / D. Diekema, S. Arbefeville, L. Boyken, J. Kroeger, M. Pfaller // Diagn Microbiol Infect Dis. – 2012. – Vol. 73. – Suppl. 1. – P. 45–48.

194. The increased role of non–albicans species in candidaemia: Results from a 3-year surveillance study / T. Y. Tan, A. L. Tan, N. W. S. Tee, et al. // Mycoses. – 2010. – Vol. 53. – Suppl. 6. – P. 515–521.

195. The epidemiology and attributable outcomes of candidemia in adults and chil- dren hospitalized in the United States: a propensity analysis. / T. E. Zaoutis, J. Ar- gon, J. Chu, J. A. Berlin, T. J. Walsh, C. Feudtner. // World Journal of Clinical In- fectious Diseases. – 2005. – Vol. 41. – Р. 1232–1239.

196. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM–2004 study / L. Pagano, M. Caira, A. Candoni, et al. // Haematologica. – 2006. – Vol. 91. – Suppl. 8. – P. 1068–1075.

197. The epidemiology of neonatal and pediatric candidemia in England and Wales,

2000–2009 / C. Oeser, T. Lamagni, P. T. Heath, M. Sharland, S. Ladhani // Pediatr

Infect Dis J. – 2013. – Vol. 32. – Suppl. 1. – P. 23–26.

198. The use of mannan antigen and anti-mannan antibodies in the diagnosis of invasive candidiasis: recommendations from the Third European Conference on Infections in Leukemia / M. Mikulska, T. Calandra, M. Sanguinetti, et al. // Critical Care. – 2010. – Vol. 14. – 222 p.

199. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multiinstitutional study / K. W. Garey, M. Rege, M. P. Pai, et al. // World Journal of Clinical Infectious Diseases. – 2006. – Vol. 43. – P. 25–31.

200. Treatment of candidemia and invasive candidiasis in the intensive care unit: post hoc analysis of a randomized, controlled trial comparing micafungin and liposomal amphotericin B / B. F. Dupont, O. Lortholary, L. Ostrosky–Zeichner, et al. // Critical Care. – 2009. – Vol. 13. –159. p.

201. Usefulness of the "Candida score" for discriminating between Candida colonization and invasive candidiasis in non-neutropenic critically ill patients: a prospective multicenter study / C. Leon, S. Ruiz-Santana, P. Saavedra, et al. // Critical Care Medicine. – 2009. – Vol. 37. – P. 1624–1633.

202. Viscoli, C. Antifungal prophylaxis and pre-emptive therapy / C.Viscoli // Drugs.

– 2009. – Vol.69. – Suppl. 1 – P. 6975–6978.

203. Wenzel, R. P. Bloodstream infections due to Candida species in the intensive care unit: identifying especially high-risk patients to determine prevention strate- gies. / Wenzel, R. P., C. Gennings. // World Journal of Clinical Infectious Diseases.

– 2005. – Vol. 41. - Suppl. 6. – Р. 389–393.

204. White, P. L. Comparison of non-culture-based methods for detection of systemic fungal infections, with an emphasis on invasive Candida infections / P. L. White, A.

E. Archer, R. A. Barnes // Journal of Clinical Microbiology. – 2005. – Vol. 43. – P.

2181–2187.

205. Wilke, M. Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin and its impact on use and costs: review of the literature

/ M.Wilke // Eur. J. Med. Res. – 2011. – Vol. 16. – P. 180–186.

206. Zilberberg, M. D. Cost-effectiveness of micafungin as an alternative to fluconazole empiric treatment of suspected ICUacquired candidemia among patients with sepsis: a model simulation. / M. D. Zilberberg, S. Kothari, A. F. Shorr // Critical Care. – 2009. – 94 p.

207. Zilderberg, M. D. Secular trends in candidemia-related hospitalization in the United States, 2000–2005 / M. D. Zilderberg, A. F. Shorr, M. H. Kollef // Infect Control Hosp Epidemiol. – 2008. – Vol. 29. – Suppl. 10. – P. 978–980.